Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

External quality assessment of HLA-B*5701 reporting: an international multicentre survey.

Hammond E, Almeida CA, Mamotte C, Nolan D, Phillips E, Schollaardt TA, Gill MJ, Angel JB, Neurath D, Li J, Giulivi T, McIntyre C, Koultchitski G, Wong B, Reis M, Rachlis A, Cole DE, Chew CB, Neifer S, Lalonde R, Roger M, Jeanneau A, Mallal S.

Antivir Ther. 2007;12(7):1027-32.

PMID:
18018760
2.
3.

The prognostic and pathophysiologic role of pro- and antiinflammatory cytokines in severe malaria.

Day NP, Hien TT, Schollaardt T, Loc PP, Chuong LV, Chau TT, Mai NT, Phu NH, Sinh DX, White NJ, Ho M.

J Infect Dis. 1999 Oct;180(4):1288-97.

PMID:
10479160
4.

Endogenous interleukin-10 modulates proinflammatory response in Plasmodium falciparum malaria.

Ho M, Schollaardt T, Snape S, Looareesuwan S, Suntharasamai P, White NJ.

J Infect Dis. 1998 Aug;178(2):520-5.

PMID:
9697735
5.

Characterization of Plasmodium falciparum-infected erythrocyte and P-selectin interaction under flow conditions.

Ho M, Schollaardt T, Niu X, Looareesuwan S, Patel KD, Kubes P.

Blood. 1998 Jun 15;91(12):4803-9.

6.

Characterization of the capsular polysaccharide of Burkholderia (Pseudomonas) pseudomallei 304b.

Masoud H, Ho M, Schollaardt T, Perry MB.

J Bacteriol. 1997 Sep;179(18):5663-9.

7.

Specificity and functional activity of anti-Burkholderia pseudomallei polysaccharide antibodies.

Ho M, Schollaardt T, Smith MD, Perry MB, Brett PJ, Chaowagul W, Bryan LE.

Infect Immun. 1997 Sep;65(9):3648-53.

8.

Promiscuity of clinical Plasmodium falciparum isolates for multiple adhesion molecules under flow conditions.

Udomsangpetch R, Reinhardt PH, Schollaardt T, Elliott JF, Kubes P, Ho M.

J Immunol. 1997 May 1;158(9):4358-64.

PMID:
9126999
9.

Structural characterization of the lipopolysaccharide O antigens of Burkholderia pseudomallei.

Perry MB, MacLean LL, Schollaardt T, Bryan LE, Ho M.

Infect Immun. 1995 Sep;63(9):3348-52.

10.

Cloning and nucleotide sequence of Pseudomonas aeruginosa DNA gyrase gyrA gene from strain PAO1 and quinolone-resistant clinical isolates.

Kureishi A, Diver JM, Beckthold B, Schollaardt T, Bryan LE.

Antimicrob Agents Chemother. 1994 Sep;38(9):1944-52.

11.

Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy.

Diver JM, Schollaardt T, Rabin HR, Thorson C, Bryan LE.

Antimicrob Agents Chemother. 1991 Aug;35(8):1538-46.

12.

Persistence of Pseudomonas aeruginosa during ciprofloxacin therapy of a cystic fibrosis patient: transient resistance to quinolones and protein F-deficiency.

Chamberland S, Malouin F, Rabin HR, Schollaardt T, Parr TR Jr, Bryan LE.

J Antimicrob Chemother. 1990 Jun;25(6):995-1010.

PMID:
2115039
14.

Characterization of mechanisms of quinolone resistance in Pseudomonas aeruginosa strains isolated in vitro and in vivo during experimental endocarditis.

Chamberland S, Bayer AS, Schollaardt T, Wong SA, Bryan LE.

Antimicrob Agents Chemother. 1989 May;33(5):624-34.

15.

Supplemental Content

Loading ...
Support Center